Anti-VEGF Therapy

How it works

Background

Evidence quality

Highlighted claims

• Bevacizumab was the first anti-angiogenic agent approved for clinical use and is now considered standard of care across multiple advanced solid tumour settings. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• The AVAGAST trial demonstrated that adding bevacizumab to chemotherapy provides clinical benefit over chemotherapy alone in advanced gastric cancer. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Anti-VEGF therapy suppresses tumour angiogenesis both by directly inhibiting tumour vasculature and by remodelling the tumour immune microenvironment to improve immune cell infiltration. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• The immunomodulatory effect of anti-VEGF therapy on the tumour immune microenvironment is proposed to synergise with PD-1 blockade, providing the basis for combining the two approaches. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial